Clinical Trials Logo

Clinical Trial Summary

The study intends to show that basimglurant provides effective seizure control in children and adolescents with Tuberous Sclerosis Complex (TSC).


Clinical Trial Description

The study drug (basimglurant) is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5) which controls a wide range of processes in the brain, spinal cord, retina, and peripheral nervous system. In animal studies, the inhibition of this receptor has shown therapeutic potential for the treatment of Tuberous Sclerosis Complex (TSC). This receptor's inhibition decreases the frequency of seizures. In previous clinical trials, the study drug has shown an advantageous safety profile in children and adolescents. The objective of this study is to find an optimal dose at which the study drug will lead to a decrease in the duration, frequency and intensity of seizures in children and adolescents with TSC, while being well tolerated. All patients who positively respond and tolerate the medicine will be offered the possibility to continue in an open label extension. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05059327
Study type Interventional
Source Noema Pharma AG
Contact
Status Not yet recruiting
Phase Phase 2
Start date November 22, 2021
Completion date May 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02687633 - Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex N/A
Completed NCT02201212 - Everolimus for Cancer With TSC1 or TSC2 Mutation Phase 2
Completed NCT01767779 - Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Recruiting NCT02098759 - Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex N/A
Recruiting NCT01730209 - Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase 2/Phase 3
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT04987463 - Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Phase 2/Phase 3
Recruiting NCT03276195 - Studies in Patients With Tuberous Sclerosis Complex
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT04112537 - Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Completed NCT01929642 - Rapalogues for Autism Phenotype in TSC: A Feasibility Study Phase 2
Completed NCT02451696 - A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Phase 2
Completed NCT01780441 - Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)
Completed NCT01289912 - Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Phase 2
Completed NCT01070316 - Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Phase 1/Phase 2
Completed NCT00598455 - Tuberous Sclerosis Complex Natural History Study: Renal Manifestations N/A
Active, not recruiting NCT02849457 - Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Phase 2
Recruiting NCT04198181 - The Effectiveness and Safety of Resective Epilepsy Surgery for TRE